Stay updated with breaking news from Active Pharma Sciences Limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
US Food and Drug Administration US FDA has successfully completed the inspection of the multipurpose API manufacturing facility of Solara Active Pharma Scienc
The US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatnam, Andhra Pradesh, with no observations. Solara confirms compliance with FDA standards. The facility, dedicated to Ibuprofen API production, marks Solara's second successful FDA inspection. The company aims for global market expansion with FDA-approved facilities.
The Board of Directors of Solara Active Pharma Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.
According to the findings of a new Future Market Insights (FMI) report, the global Ibuprofen API Market crossed US$ 626.2 Million in 2022 and is expected to grow at a CAGR of 3% to reach US$ 772.2 Million by 2029. The key drivers of the Ibuprofen API market are the ongoing need for low-cost nonsteroidal anti-inflamm...
Solara Active Pharma Sciences Limited has successfully completed the inspection carried out by the World Health Organization at its Cuddalore facility, Tamil Nadu between January 23 – 26, 2023.